PRGO Share Price

Open 73.51 Change Price %
High 74.93 1 Day -1.58 -2.10
Low 72.68 1 Week -3.07 -4.01
Close 73.48 1 Month -11.50 -13.53
Volume 3372844 1 Year -75.10 -50.55
52 Week High 151.50
52 Week Low 72.68
PRGO Important Levels
Resistance 2 75.57
Resistance 1 74.71
Pivot 73.70
Support 1 72.25
Support 2 71.39
NASDAQ USA Most Active Stocks
ASTI 0.01 0.00%
QCOM 54.88 -12.72%
QCOM 54.88 -12.72%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
EDMC 0.02 100.00%
CPSL 0.10 66.67%
LOCM 0.09 50.00%
ACFN 0.30 30.43%
LTRE 2.85 29.55%
WRES 0.09 28.57%
QKLS 0.14 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Perrigo Company (NASDAQ: PRGO)

PRGO Technical Analysis 5
As on 23rd Jan 2017 PRGO Share Price closed @ 73.48 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 97.76 & Strong Sell for SHORT-TERM with Stoploss of 83.95 we also expect STOCK to react on Following IMPORTANT LEVELS.
PRGO Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
PRGO Other Details
Segment EQ
Market Capital 10823602176.00
Sector Healthcare
Industry Drug Related Products
Offical website http://www.perrigo.com
PRGO Address
PRGO
Treasury Building
Lower Grand Canal Street
Dublin, 2
Ireland
Phone: 353 1 604 0031
Interactive Technical Analysis Chart Perrigo Company ( PRGO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Perrigo Company
PRGO Business Profile
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri. Its businesses include Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, API, Life Sciences and Other Businesses. The Company offers Healthcare Products across a range of product categories primarily in the United States, the United Kingdom, Mexico, Israel and Australia. In February 2013, it completed the acquisition of Leeds, United Kingdom-based Rosemont Pharmaceuticals Ltd. In April 2013, it closed the acquisition of Velcera, Inc. In June 2013, the Company acquired an ophthalmic sterile ointment and solution product portfolio from Fera Pharmaceuticals, LLC. In December 2013, it acquired Elan Corporation Plc.